Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: Results from a prospective open-label study

Plastic and Reconstructive Surgery

Volumn 120, Issue 5, 2007, Pages 1386-1393

  Stotland, Mitchell A ^a   Kowalski, Jonathan W ^b   Ray, Belinda B ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ABNORMAL SENSATION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FACE MUSCLE; FEMALE; GLABELLAR RHYTIDES; HEADACHE; HUMAN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; OPEN STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SELF CONCEPT; SELF REPORT; SKIN DEFECT; TREATMENT OUTCOME;

ADULT; BODY IMAGE; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; MIDDLE AGED; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SELF CONCEPT; SKIN AGING;

EID: 34848925836     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.prs.0000279377.86280.8d     Document Type: Article

References (11)

1. Song, K. H. Botulinum toxin type A injection for the treatment of frown lines. Ann. Pharmacother. 32: 1365, 1998.
2. Finn, J. C., Cox, S. E., and Earl, M. L. Social implications of hyperfunctional facial lines. Dermatol. Surg. 29: 450, 2003.
3. Khan, J. A. Aesthetic surgery: Diagnosing and healing the miscues of human facial expression. Ophthal. Plast. Reconstr. Surg. 17: 4, 2001.
4. Botox Cosmetic (botulinum toxin type A) prescribing information. Irvine, Calif: Allergan, Inc., 2004.
5. Carruthers, J. D., and Carruthers, J. A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J. Dermatol. Surg. Oncol. 18: 17, 1992.
6. Carruthers, J. D., Lowe, N. J., Menter, M. A., et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast. Reconstr. Surg. 112: 1089, 2003.
7. Foster, J. A., Barnhorst, D., Papay, F., et al. The use of botulinum A toxin to ameliorate facial kinetic frown lines. Ophthalmology 103: 618, 1996.
8. Sommer, B., Zschocke, I., Bergfeld, D., et al. Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines. Dermatol. Surg. 29: 456, 2003.
9. Cox, S. E., Finn, J. C., Stetler, L., et al. Development of the Facial Lines Treatment Satisfaction Questionnaire and initial results for botulinum toxin type A-treated patients. Dermatol. Surg. 29: 444, 2003.
10. Kowalski, J. W., Cox, S. E., Finn, C., et al. Development, validity, and reliability of the Facial Lines Treatment Satisfaction (FTS) Questionnaire. Poster 293 presented at the 9th Annual Meeting of the International Society for Quality of Life Research (ISOQOL), Orlando, Florida, October 30 through November 2, 2002.
11. Heckmann, M., Teichmann, B., Schröder, U., et al. Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. J. Am. Acad. Dermatol. 49: 213, 2003.